280 Bio gets US FDA approval to begin phase 1 trial of novel KRAS inhibitor, YL-17231
280Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, announced that the US Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the investigational drug YL-17231, a small molecule inhibitor of RAS signalling. The approval enables the initiation of the phase 1 clinical study for YL-17231 in the US.
KRAS, NRAS and HRAS genes are frequently mutated in many tumour indications with the oncogenic mutations leading to tumour cell growth. YL-17231 demonstrated in pre-clinical research to potently inhibit tumour cell proliferation in vitro and in vivo, exhibiting activity with a variety of RAS mutations, including tumours that have become resistant to KRAS G12C inhibitors. 280Bio will initiate a phase 1 study for the treatment of advanced cancer patients with RAS mutations in their tumours.
“The IND approval by the FDA enables 280Bio to initiate the phase 1 clinical trial of our novel KRAS inhibitor marking a major milestone for the company’s clinical development programme.” said Michael Hui, chief executive officer of 280Bio Inc., “We are excited to explore the therapeutic potential of YL-17231 targeting a broad patient population with RAS mutations to potentially create a transformative therapy option.”
280Bio will advance YL-17231 into a US-based phase 1 clinical study at multiple clinical cancer research centres in the US including the MD Anderson Cancer Center, Houston, Texas. The company plans to start enrollment of patients in the dose escalation part of phase1 in the fourth quarter of 2023.
Reflecting on the high unmet need for newly developed cancer agents, Dr. Zusheng Xu, general manager and head of research and development of Yingli Pharma, said “We are excited that YL-17231 has emerged from the company’s discovery platform, exemplifying the utility of our strong medicinal chemistry capabilities. YL-17231 has a broader activity than many current KRAS inhibitors and demonstrated strong inhibition of in vivo KRAS mutant xenograft tumour growth in our preclinical investigations. With its excellent pharmacologic properties, we are hopeful that YL-17231 will demonstrate to be safe and efficacious during continuous oral dosing in patients.”
YL-17231 has been co-developed by 280Bio and Yingli Pharma and emerges from the strategic collaboration of 280Bio with The University of Texas MD Anderson Cancer Center, where further preclinical research of the investigational drug is continuing.
280Bio, headquartered in the San Francisco Bay Area, is developing innovative precision small molecule inhibitors for the treatment of cancer. 280Bio is a clinical-stage biotechnology company and a wholly owned subsidiary of Shanghai Yingli Pharmaceutical Co., Ltd., Shanghai, China (Yingli Pharma).
